Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

83.21
+0.44500.54%
Post-market: 82.04-1.1650-1.40%18:05 EDT
Volume:733.66K
Turnover:61.04M
Market Cap:3.65B
PE:-76.87
High:84.50
Open:82.76
Low:81.95
Close:82.76
52wk High:85.25
52wk Low:48.20
Shares:43.88M
Float Shares:32.68M
Volume Ratio:0.78
T/O Rate:2.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:10.53
PE(LYR):-52.33

Loading ...

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 27

Tarsus Pharmaceuticals (TARS) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Assessing Tarsus Pharmaceuticals (TARS) Valuation After New TP-05 Phase 2b Lyme Disease Trial Update

Simply Wall St.
·
May 22

Tarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors

TIPRANKS
·
May 21

Tarsus and John Cena Partner to Raise Awareness of Demodex Blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

THOMSON REUTERS
·
May 14

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

GlobeNewswire
·
May 14

Mizuho Securities Remains a Buy on Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
May 08

Tarsus Pharmaceuticals (TARS) Gets a Buy from Guggenheim

TIPRANKS
·
May 08

Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 08

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 08

Tarsus Pharmaceuticals Earnings Call Signals Durable Growth

TIPRANKS
·
May 07

Tarsus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Tarsus Q1 FY26 net loss narrows to $7 million; net product sales rise 85% to $145.4 million

Reuters
·
May 07

Tarsus Pharmaceuticals Q1 EPS $(0.16) Beats $(0.33) Estimate, Sales $162.054M Beat $148.422M Estimate

Benzinga Earnings
·
May 07

BRIEF-Tarsus Pharmaceuticals Q1 EPS USD -0.16

Reuters
·
May 07

Tarsus Pharmaceuticals Inc - Reaffirms FY2026 Xdemvy Net Product Sales Guidance of $670 Mln-$700 Mln

THOMSON REUTERS
·
May 07

Tarsus Pharmaceuticals Q1 Revenue USD 145.387 Million VS. Ibes Estimate USD 148.4 Million

THOMSON REUTERS
·
May 07

Tarsus Pharmaceuticals - Reaffirmed Full-Year 2026 Guidance of $670-700 Million of Xdemvy Net Product Sales

THOMSON REUTERS
·
May 07

LifeSci Capital Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
May 06